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Abstract 24 
The chicken or fish derived tripeptide, Leucine-Lysine-Proline (LKP), inhibits the 25 
Angiotensin Converting Enzyme and may be used as an alternative treatment for pre-26 
hypertension. However, it has low permeation across the small intestine. The formulation of 27 
LKP into a nanoparticle (NP) has the potential to address this issue. LKP-loaded NPs were 28 
produced using an ionotropic gelation technique, using chitosan (CL113). Following 29 
optimisation of unloaded NPs, a mixture amount design was constructed using variable 30 
concentration of CL113 and tripolyphosphate at a fixed LKP concentration. Resultant 31 
particle sizes ranged from 120-271 nm, zeta potential values from 29-37 mV and 32 
polydispersity values from 0.3-0.6. A ratio of 6:1 (CL113: TPP) produced the best 33 
encapsulation of approximately 65%. Accelerated studies of the loaded nanoparticles 34 
indicated stability under normal storage conditions (room temperature). Cytotoxicity 35 
assessment showed no significant loss of cell viability and in vitro release studies indicated 36 
an initial burst followed by a slower and sustained release. 37 
 38 
Keywords: chitosan nanoparticles; food derived peptide; mixture amount design; accelerated 39 
thermal stability analysis; ACE inhibition  40 
1. Introduction 41 
A number of synthetic antihypertensive drugs (ACE inhibitors) are currently available on the 42 
market (e.g. captopril, lasinopril and enalapril) but all have been reported to have associated 43 
adverse side effects, such as coughing, dizziness, loss of taste and skin rashes and poor 44 
pharmacokinetics with a short half life, resulting in the requirement of frequent dosage 45 
(Bougatef et al., 2008). Therefore, natural ACE inhibitors, isolated from food sources, have 46 
attracted increasing attention in recent years, in the search to find a safer and more 47 
economical approach for the consumers (Bougatef et al., 2008). Peptides derived from food 48 
sources have been reported to have health benefits such as hypotensive activity, due to their 49 
Angiotensin Converting Enzyme (ACE) inhibitory activity (Berilyn et al., 2016; Li et al., 50 
2016). Using DNA microarray experiments it was found that other mechanisms can also 51 
contribute to the decrease of blood pressure for bioactive tripeptides (Yamaguchi, 52 
Kawaguchi, & Yamamoto, 2009) reducing the side effects of ACE inhibition. However, 53 
exploitation of the potential nutraceutical benefits of these peptides in general is known to 54 
face a number of challenges. Insufficient gastric residence time, low permeation and/or 55 
solubility within the gut, chemical degradation within the gastrointestinal tract (GIT) due to 56 
low pH, enzymatic degradation, and the presence of other nutrients (in food), all limit the 57 
bioavailability of bioactive peptides by the oral delivery route (Braithwaite et al., 2014; Ma, 58 
2014; Segura-Campos, Chel-Guerrero, Betancur-Ancona, & Hernandez-Escalante, 2011). A 59 
number of researchers have attempted to formulate peptides into oral delivery systems for 60 
example by the addition of absorption enhancers (Choonara et al., 2014), enzyme inhibitors 61 
(Bruno, Miller, & Lim, 2013), hydrogels (Sharpe, Daily, Horava, & Peppas, 2014), liposomes 62 
(Takahashi, Uechi, Takara, Asikin, & Wada, 2009) and nanoparticles (Yao, McClements, & 63 
Xiao, 2015).  64 
Leucine-Lysine-Proline is a tripeptide, derived from chicken muscle, which has shown in 65 
vitro ACE inhibitory activity, having a mean inhibitory concentration (IC50) of 0.32µM 66 
(Zhou, Du, Ji, & Feng, 2012). In addition, LKP has been shown to elicit a significant 67 
reduction of blood pressure in spontaneously hypertensive rats (SHR) when delivered 68 
intravenously, 10mg/kg
-1
 producing a reduction in systolic blood pressure of 75mmHg, 69 
compared to an oral dose of 60mg/kg
-1
, which resulted in a reduction of 18mmHg (Fujita, 70 
Yokoyama, Yoshikawa, Iroyukifujita, & Eiichiyokoyama, 2000). Captopril, a synthetic oral 71 
ACE inhibitor drug used for the treatment of hypertension, has been reported by Quiñones et 72 
al. (2015) to show a maximum in vivo change in SHR of 60.5 ± 2.7 mmHg, 4 hours post-73 
administration, when 50mg/kg was given orally . Recent studies have shown that LKP is 74 
stable in the GIT but with lower permeation than the market drugs, across the intestine at its 75 
target site, the small intestine (Gleeson, Heade, Ryan, & Brayden, 2015). Formulation into 76 
nanoparticles (NPs) for oral delivery can enhance the bioavailability of an encapsulated 77 
peptide drug and consequently improve its pharmacokinetics and stability (Patel, Patel, Yang, 78 
& Mitra, 2014; Ryan et al., 2013). Stable NPs with particle sizes ranging between 100-500nm 79 
(des Rieux, Fievez, Garinot, Schneider, & Préat, 2006), zeta potential values (ZP) ≥ 30mV 80 
(Lakshmi & Kumar, 2010), polydispersity (PDI) < 0.400 (Abdel-Hafez, Hathout, & 81 
Sammour, 2014a) and maximum encapsulation efficiency are ideal characteristics for oral 82 
supplementation.  83 
Chitosan is a linear polysaccharide, prepared by N-deacetylation of chitin (Rinaudo, 2006). 84 
Chitosan NPs have shown promising results for oral delivery/supplementation due their 85 
GRAS properties and their intrinsic properties, including, non-immunogenic, mucoadhesion 86 
and the ability to transiently open the tight junctions of the intestinal barrier, which can help 87 
facilitate transport of macromolecules and has the potential to act as an enhancer (Chuah, 88 
Kuroiwa, Ichikawa, Kobayashi, & Nakajima, 2009; de Moura et al., 2009; Madureira, 89 
Pereira, & Pintado, 2016). LKP NPs were produced using an ionotropic gelation technique. 90 
This technique allows the preparation of chitosan NPs in aqueous solution and avoids the use 91 
of organic solvents, high dispersion energy and harsh conditions, making the technique 92 
suitable for the inclusion of nutraceuticals (García, Forbe, & Gonzalez, 2010). In this process, 93 
a chitosan with a high degree of deacetylation is used, which increases the viscosity and 94 
results in an extended conformation with a more flexible chain because of the charge 95 
repulsion in the molecule (Franca, Freitas, & Lins, 2011). Chitosan can be ionically cross-96 
linked by counterions, such as sodium tripolyphosphate (TPP), to form a hydrogel of 97 
microparticles, and when the relative concentrations of chitosan and these anions are 98 
appropriate, NPs may be generated (Sureshkumar, Das, Mallia, & Gupta, 2010). 99 
The formulation of NPs from different constituent components can be troublesome, due to the 100 
different variable parameters used (concentration, temperature and pH). Empirical 101 
optimisation using Response Surface Modelling (RSM) can help to rationalise the process 102 
and has found applications in different fields, such as engineering, pharmaceutical, 103 
biomedical, environmental and epidemiological research (Singh, Singh, Saraf, & Saraf, 104 
2011). RSM has been shown to be useful for optimisation of experimental parameters in 105 
nanoparticle formulation, and has been adopted by a number of research groups (Abdel-106 
Hafez, Hathout, & Sammour, 2014b; Bezerra, Santelli, Oliveira, Villar, & Escaleira, 2008).  107 
The aim of this work is to formulate and investigate the feasibility of LKP encapsulated 108 
chitosan NPs, determining the physico-chemical characteristics, stability to storage, 109 
bioactivity and low cytotoxicity properties. The formulation of the LKP NP was optimised 110 
using a RSM approach.  The physico-chemical characteristics of the NPs were assessed using 111 
dynamic laser scattering, scanning electron microscopy, and Fourier transform infrared 112 
spectroscopy, with the aim of producing the optimal NPs as an oral delivery system. 113 
Accelerated thermal conditions are employed to explore the stability for future storage 114 
conditions; particle size, polydispersity, zeta potential and bioactivity were assessed. In 115 
addition, the cytotoxicity and release profiles in simulated gastric and intestinal fluids were 116 
assessed. 117 
2. Materials and Methods 118 
LKP (Mw 356.47, purity = 96% according to the manufacturer’s specifications) was 119 
synthesised by ChinaPeptides Co. Ltd, (Shanghai, China). CL113 (Mw = 110 kDa, 120 
deacetylation degree (DD) = 86% according to manufacturer’s specifications) was obtained 121 
from Pronova Biopolymer (Norway). TPP, Angiotensin-I converting enzyme (from rabbit 122 
lung), captopril, N-α-hippuryl-L-histidyl-L-leucine hydrate salt (HHL) and all other materials 123 
were obtained from Sigma-Aldrich (Ireland). CellTitre 96® AQueous One Solution Cell 124 
Proliferation Assay was supplied by Promega (Madison, USA). Caco-2 cells (passage 24-26) 125 
were obtained from European Collection of Cell Cultures (Salisbury, UK). HepG2 cells 126 
(passage 32-34) were obtained from American Type Culture Collection. Ultrapure water was 127 
used for all experiments and was obtained from a Milli-Q water purification system 128 
(Millipore Corporation, USA).  129 
2.1 Unloaded nanoparticle formulation design 130 
Unloaded NPs formulation was optimised using varying concentrations of CL113 and TPP, 131 
following a 3 block Central Composite Design (CCD) with 2 variable parameters and 3 132 
responses (particle size, ZP and PDI). 133 
2.2 LKP nanoparticle formulation design 134 
A Mixture Amount Design (MAD) was employed using the concentration ranges of chitosan 135 
(CL113) and TPP (see table 1) around the optimal point (1.5mg/mL CL113 and 0.3mg/mL 136 
TPP) suggested from preliminary unloaded particle experiments (Section 3.1). The 137 
experimental design and data analysis was performed using Minitab 17 software (Minitab 138 
Inc, USA).  139 
Table 1 MAD for LKP nanoparticles at optimised CL113, TPP concentration 140 
Sample  CL113 (mg/ml) TPP (mg/ml) Ratio (CL113/TPP) 
1 1.64 0.21 8.0 
2 1.52 0.33 4.5 
3 1.58 0.27 5.9 
4 1.45 0.40 3.6 
5 1.39 0.46 3.0 
 141 
2.3 Preparation of LKP NPs 142 
Preparation of LKP NPs was based on a modified ionotropic method (Calvo, Remu, Pez, 143 
Vila-Jato, & Alonso, 1997; Vimal et al., 2013). Stock solutions of 10mg/mL CL113 and TPP 144 
were prepared. CL113 was dispersed in acetate buffer (pH3) and TPP in 0.01M sodium 145 
hydroxide solution. The stock solutions of CL113 and TPP were diluted to different 146 
concentration ratios at a fixed volume mixture of 2.5:1 CL113: TPP containing solution. A 147 
fixed concentration of 0.1mg/mL LKP was added to the diluted TPP solutions. The 148 
TPP/peptide solution was added dropwise to the CL113 solution while stirring (800rpm for 149 
30mins). NPs were separated using ultrafiltration-centrifugation (Centriplus YM-30, MWCO 150 
of 30kDa, Millipore, USA). 10mL of sample were placed in the sample reservoir of the 151 
centrifugal filter device and centrifuged for 30mins at 3000rpm. After separation, the volume 152 
of the solution in the filtrate vial was measured and the filtrate was assayed for the amount of 153 
LKP by Reverse Phase High Performance Liquid Chromatography (RP-HPLC). The wet 154 
pellet was re-suspended in purified water and immediately characterised using a range of 155 
physico-chemical techniques. 156 
2.4 Physico-chemical characterisation of LKP NPs 157 
2.4.1 Size, zeta potential and polydispersity index  158 
The nanoparticle size (number distribution) and electrophoretic mobility measurements were 159 
performed using folded capillary cells in a Nanosizer ZS fitted with a 633 nm laser (Malvern 160 
Instruments Ltd.). Each analysis was carried out at 25°C with the equilibration time set to 2 161 
min using size by intensity distribution. 162 
2.4.2 Fourier transform infrared spectroscopy 163 
The chemical properties of the NPs were monitored using Fourier transform infrared 164 
spectroscopy (FT-IR), performed using a Perkin Elmer Spotlight 400 Series Spectrometer 165 
(with Universal Attenuated total reflectance (ATR) accessory). FT-IR spectra of LKP, 166 
unloaded NPs, and LKP NPs were obtained in the spectral range 650 to 4000 cm
-1 
in 167 
triplicate. NP samples were stored at -80˚C in glass vials and then lyophilised prior to 168 
analysis using a Labconco FreeZone 6 Liter Benchtop Freeze Dry System. 169 
2.4.3 Scanning electron microscopy  170 
The morphology of the freeze-dried NPs was studied using scanning electron microscopy 171 
(SEM) (Hitachi SU6600 FESEM), at an accelerating voltage of 20kV using the secondary 172 
electron detector. The freeze dried NPs (0.5mg) were dispersed in deionised water (10mL) 173 
and sonicated for 4min. One drop of the dispersion containing LKP NPs was placed on a 174 
silicon wafer and dried at room temperature. This was sputter coated with 4nm Au/Pd prior to 175 
imaging. 176 
2.4.4 Determination of association efficiency and loading capacity of LKP nanoparticles 177 
The association efficiency (AE) and loading capacity (LC) of NPs was calculated by the 178 
indirect method of Al-Qadi et al. (2012). The supernatant was assayed for the content of LKP 179 
by RP-HPLC. This quantity of LKP is referred to as the non-associated peptide. The RP-180 
HPLC analysis was performed on a Waters 1525 pump (Waters, Milford, Massachusetts) 181 
with a Photo Diode Array detector 2487 (Waters) using a Luna C18 column (5µm, 250mm x 182 
4.6mm, Phenomenex). Analytes were detected at the wavelength of λmax= 220nm. The 183 
column was eluted at a flow rate of 1mL.min
−1
 with an isocratic system (15% Acetonitrile, 184 
0.05% TFA in water). The AE% and loading capacity (LC %) was calculated using the 185 
following equations. 186 
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2.4.5 ACE inhibition assay 189 
The ACE inhibition of LKP was determined as previously described with minor 190 
modifications (Henda et al., 2013; Lahogue, Réhel, Taupin, Haras, & Allaume, 2010). All 191 
solutions were pre-filtered with 0.22µm nylon syringes prior to analysis. HHL (5mM) was 192 
dissolved in pH 8.3 buffer (0.1M borate buffer in 0.3M NaCL). In a 96-well plate, 100µl 193 
substrate solution and 25µl inhibitor were incubated for 10min at 37°C. 10µl ACE solution 194 
(100mU/mL) was then added and incubated for another 30min at 37°C. The assay was 195 
terminated using 100µ1 of 1M HCL. HPLC was performed using a C8 column (2.7µm, 3.0 x 196 
100mm, Agilent Technologies UK & Ireland Ltd) and  wavelength detection at λmax= 228nm. 197 
An isocratic method was used at a flow rate of 0.4mL.min
-1
, 25% Acetonitrile, 0.1% TFA in 198 
water for 5min. Controls were prepared by replacing the inhibitor with assay buffer (negative 199 
control) and captopril (positive control). 100% ACE inhibition (negative control) was used to 200 
calculate the % of ACE activity. 201 
                   (  
          
      
)                     (4.3) 202 
where Ainhibitor and Ablank are the peak areas of HA (product of HHL) and negative control, 203 
respectively. The IC50 of the inhibitor was determined using the Hill-Step equation (Prism 5, 204 
GrapPad Software Inc., USA).  205 
2.4.6 Accelerated stability analysis 206 
The optimal formulation was further analysed under accelerated stability conditions. 10mL of 207 
a NP formulation equivalent to 19.5mg of NPs were resuspended in aqueous solution (pH7) 208 
and stored at accelerated conditions; 60°C for 720min, 70°C for 300min and 80°C for 209 
120min. The particle size and colloidal stability over different time intervals were measured 210 
using the Nanosizer ZS (Malvern Instruments Ltd), and the order of degradation in aqueous 211 
LKP suspension was determined. The end point of each sample was further assessed for ACE 212 
inhibition activity (Method 2.4.5). Stability analysis was analysed using R software (R Core 213 
Team, 2015). 214 
The kinetic model used to describe the stability was of zero order. The temperature 215 
dependence of the kinetic parameters of LKP NPs stability was measured by calculating the 216 
observed rate constants. This was plotted according to the Arrhenius equation and apparent 217 
activation energy, Ea and reaction rate, kref were calculated according to Equation 4 (Brauner 218 
& Shacham, 1997). 219 
      
      
  
 
(
 
 
 
 
    
)
                       (4.4) 220 
where C is the property (particle size or PDI) at time t, Co is the initial property conditions, k 221 
is the apparent zero order reaction constant, Ea is the energy of activation, R is the universal 222 
gas constant, T is the temperature of the experiment (K) and Tref is the reference temperature 223 
(70°C). 224 
2.4.7 MTS assay 225 
Caco-2, heterogeneous human epithelial colorectal adenocarcinoma cells and HepG2, a 226 
human liver cancer cell line, were seeded at a cell density of 2 x 10
4
 cells/well and cultured 227 
on 96 well plates in DMEM and EMEM respectively, supplemented with 10% fetal bovine 228 
serum, 1% L-glutamine, 1% penicillin-streptomycin and 1% non-essential amino acids, and 229 
incubated for 24h at 37°C in a humidified incubator with 5% CO2 and 95% O2. Specified 230 
exposure times were used for Caco-2 and HepG2, in order to mimic in vivo conditions. The 231 
maximum time NPs will be exposed to the intestines are 4h, hence a 4h exposure time was 232 
used in Caco-2 cell lines (Neves, Martins, Segundo, & Reis, 2016). In addition to this, 72h 233 
exposure time was used for HepG2 cell line to mimic the liver (Brayden, Gleeson, & Walsh, 234 
2014). LKP (native), unloaded NP and LKP NPs at 1, 5 and 10mM concentration were 235 
assessed. Triton X-100™ (0.05%) was used as a positive control. After exposure, treatments 236 
were removed and replaced with MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carbo237 
xymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium. Optical density (OD) was measured at 238 
490 nm. Each value presented was normalised against untreated control and calculated from 239 
three separate experiments, each of which included six replicates. 240 
2.4.8 In vitro controlled release studies 241 
LKP release from loaded formulation was carried out using a dialysis bag diffusion technique 242 
(Hosseinzadeh, Atyabi, Dinarvand, & Ostad, 2012) over 24h (Calderon et al., 2013; Yoon et 243 
al., 2014). To ensure sink conditions, NPs were solubilised and sonicated 3 times for 20 244 
seconds (Branson Ultrasonics; Ultrasonic processor VCX-750W, Wilmington, North 245 
Carolina, USA). 5mL of LKP formulation was placed in the dialysis bag (cellulose ester 246 
membrane, molecular weight cut-off 100kDa, Float-A-Lyzer
®
G2, Sigma-Aldrich, Ireland) 247 
and immersed in a vessel containing 50mL of release fluid using simulated gastric fluid 248 
(SGF) or simulated intestinal fluid (SIF) specified according to the British Pharmacopoeia, 249 
respectively. SGF was composed of 0.1 M HCL and SIF, as the buffering stage, was 250 
composed of 1 volume of 0.2 M trisodium phosphate dodecahydrate and 3 volumes of 0.1 M 251 
HCL (adjusted to pH 6.8), without enzymes (British Pharmacopoeia Commission, 2016). 252 
Each experiment was agitated at 100rpm, 37◦C using a thermostatic shaker. At predetermined 253 
time points over 24h, 1mL of release fluid was analysed and replaced with simulated fluid. 254 
The LKP release was measured using RP-HPLC. The following equation was employed to 255 
determine the % cumulative drug release: 256 
                     
           
            
                        (4.5)        257 
where LKP release and initial represents the concentration of LKP release and the amount of 258 
LKP initially loaded into the NPs, respectively.  259 
3. Results and discussion 260 
LKP has an isoelectric point (pI) of 9.17, calculated using the Henderson-Hasselbach 261 
equation (Henriksson, Englund, Johansson, & Lundahl, 1995). This is the net charge of a 262 
molecule indicating that, at a pH of 9.17, LKP will have minimal solubility. At pH values 263 
below the pI, peptides carry a net positive charge and above the pI, a negative charge. LKP 264 
has a similar charge to TPP, and hence LKP was dissolved in the TPP solution. TPP-LKP 265 
was then added dropwise to the CL113 solution, resulting in the formation of opalescent NPs. 266 
3.1 Unloaded nanoparticle production feasibility zone identification 267 
The formulation of CL113 NPs was optimized using a CCD factorial design to analyse the 268 
effect of the pH, CL113: TPP ratio and acetic acid concentration on the size and ZP of the 269 
particles. Preliminary studies were conducted to select the most feasible region for the 270 
formulation of peptide NPs (figure 1). This showed that > 1.25 mg/mL CLL113 and 0.25-0.3 271 
mg/mL TPP resulted in unloaded NPs of optimal sizes of 300 nm and ZP > 30 mV. 272 
 273 
Figure 1 Overlaid contour plots of Size and ZP: the targeted area is highlighted (white). 274 
This result is in agreement with Calvo et al., (1997) who reported that concentrations which 275 
exceed 4mg/mL and 0.75mg/mL respectively for chitosan and TPP resulted in the  formation 276 
of  large aggregates. Nanoparticles of the desired characteristics were found to be produced at 277 
concentrations of 0.28 mg/mL (TPP) and 1.25 mg/mL (Chitosan). In addition, studies done 278 
by de Pinho Neves et al. (2014) showed similar results within the 5 to 6:1 ratio. Unloaded 279 
CL113 NPs were used as control for peptide-loaded experiments.  280 
3.2 Nanoparticle size, zeta potential analysis and AE % of LKP nanoparticles 281 
From the preliminary optimisation analysis of unloaded CL113 NPs; a CL113 concentration 282 
of 1.5mg/mL was chosen as the centre point for the MAD. LKP NP size values ranged from 283 
120 to 271nm, with ZP values above 30mV. With regards to the AE % (figure 2), at ratios 284 
above 5.9, there is less variability (error bars), but at a ratio of 8, stable agglomerates (> 285 
30mV ZP) of variable sizes are observed. 286 
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Figure 2 Scatterplot of (a) Size (nm), (b) PDI, (c) ZP (mV) and (d) association efficiency 288 
(AE %) of LKP NPs against different ratios of (CL113/ TPP). Error bars represent the 289 
individual 95% Confidence interval for the average 290 
An initial observation of the results at different ratios seems to indicate that the ratio of 5.9 is 291 
the best performing in terms of higher AE% and lower PDI, while still maintaining a particle 292 
size (150nm) and a ZP (>30mv) that indicates stability (figure 2). LC% for all experiments 293 
showed no significant differences, values ranged from 2-3% (see supplementary material, S2) 294 
were attained. Studies from other groups showed that an increase of counterion (TPP) 295 
concentration results in a decrease of LC due to the high level of crosslinking, causing the 296 
encapsulated material to come out of the particle (Woranuch & Yoksan, 2013).  297 
Similar profiles are seen for the 3 responses, size (nm), ZP (mV) and PDI, suggesting 298 
agglomeration and colloidal instability above a ratio (CL113/TPP) of 7. The degree of 299 
crosslinking can be assessed by the chitosan concentration and the available NH3+ able to be 300 
crosslinked with TPP functional groups. At intermediate operation conditions, i.e. ratios 301 
between 7 and 5.5, most responses present a lower variation between replicates with respect 302 
to all responses and a minimum PDI. Analysis for all experimental results shows particle 303 
sizes within the optimal size range (100-500nm) and ZP above 30mV values. However, for 304 
some experimental conditions, the AE% and PDI exhibited values far from the optimal 305 
physico-chemical characteristics and had high variability between replicates (N=3). At 306 
(CLL113/TPP) ratios above 7 and below 4.5, the NPs exhibited higher PDI and, below a ratio 307 
of 6, significant variability of AE% amongst replicates is evident. 308 
The results obtained were consistent with those observed for unloaded CL113 NPs in terms 309 
of particle size, although a significant increase in colloidal stability for the loaded NPs was 310 
observed (see figure 3). 311 
 312 
Figure 3 Boxplot for LKP NPs where each Group represents 1: control (unloaded NPs) and 313 
2: LKP NPs. The changes of each group are examined for A: particle size, B: ZP and C: PDI. 314 
A significant increase in ZP is seen for loaded NPs with a decrease of variability. 315 
For the MAD design, a third order polynomial regression model was employed to describe 316 
the variation of size (nm), ZP (mV), PDI and AE % of the LKP NPs against the ratio 317 
(CL113/TPP). The polynomial equation parameters for each response against ratio were 318 
fitted. The models were built with the aim of identifying conditions within the experimental 319 
design where NPs would be present as monodispersed, stable NPs with maximum peptide 320 
encapsulation (see supplementary information S1).  321 
From the results obtained, a ratio of 5.9 provided the most promising results, for optimal oral 322 
delivery fulfilling the formulation constraints; 100-500 nm, PDI <0.4 and |ZP| >30 mV. In 323 
comparison, NPs produced at a ratio of 7.8, presented the highest variability for size (206 ± 324 
73 nm), PDI (0.4 ± 0.2), ZP (38 ± 6 mV) and AE (41 ± 11%). Notably, the NPs produced at a 325 
ratio of 5.9 (CL113/TPP) yielded a substantially higher AE % of around 65%. It should be 326 
noted that the LKP of isoelectric pH (9.17) was added to a higher pH TPP (pH 12) solution. 327 
This provided more negatively charged molecules to interact with chitosan, consequently 328 
increasing the AE % (Acton, 2012). This finding is in agreement with Silva et al.,(2013), who 329 
observed higher AE % of daptomycin at higher pH values relative to the isoelectric pH. In 330 
addition, LKP has a low Mw and studies of lower Mw actives showed higher AE %. This 331 
trend was observed by Jarudilokkul et al., (2011), who showed that α-Lactalbumin (17.4 kDa) 332 
has higher AE % than Fibrinogen (340 kDa). 333 
3.3  Morphological characterisation of LKP chitosan nanoparticles 334 
Further characterisation of the NPs produced with the optimal (CL113/TPP) ratio of 5.9 was 335 
performed. Figure 4 represents an SEM image of LKP formulation, confirming the formation 336 
of the NPs. Spheroidal NPs were obtained, of sizes ranging from 150-250nm, consistent with 337 
the DLS measurement. 338 
 339 
Figure 4 SEM image of optimal formulation (Ratio 5.9) of LKP NPs  340 
3.4 Chemical Characterisation of LKP nanoparticles 341 
FT-IR was used to identify whether there were variations in chemical functional groups 342 
presented in the LKP loaded NPs with respect to their raw materials. An FT-IR analysis was 343 
conducted for pure LKP powder, unloaded NPs and LKP NPs (Figure 5). Chitosan NPs have 344 
been previously characterised using FT-IR (Mohammadpour Dounighi et al., 2012; 345 
Sureshkumar et al., 2010; Vimal et al., 2013). 346 
Comparison of the FT-IR spectra of loaded and unloaded NPs indicated that the spectrum of 347 
the unloaded NPs is largely unchanged by the presence of LKP, as may be expected due to 348 
the relatively low LKP content. Characteristic peaks of unloaded NPs are seen in both, at 349 
1530, 1636 and 880cm
-1
, representing the amide I and amide II bands of CL113 and pyranose 350 
(P-O) of TPP. For the optimal formulation, 18.5mg of NPs is needed to encapsulate 1mg of 351 
LKP. Hence, no distinctive peaks of LKP can be seen in the LKP spectrum. The FT-IR 352 
spectrum of LKP NPs does, however, show some changes from that of the unloaded NPs, 353 
potentially indicative of localised conformational changes of the CL113 as a result of 354 
interaction with the LKP (figure 5). An increased absorption at 3386cm
-1 
compared to that of 355 
the unloaded NPs is observed. Absorption in this region of the spectrum represents O-H 356 
bonding; a possible explanation may be due to the interaction of the hydrogen acceptors (O- 357 
in LKP) and hydrogen donors (NH3+ in chitosan). In addition, increased absorption is also 358 
seen for LKP NPs at 2955cm
-1
, representing an increase in (C-H) hydrogen bond stretching 359 
with presence of the peptide. A shift of 1605cm
-1
 to 1530cm
-1 
was also observed which 360 
represent the amide carbonyl stretch (Mohammadpour Dounighi et al., 2012). The peaks at 361 
1210cm
-1
 and 880cm
-1
 represent phosphate group (P-O) and pyranose ring (Woranuch & 362 
Yoksan, 2013). The peak at 1051cm
-1
 shows a split for the loaded NPs, suggesting a 363 
conformational change due to the interaction with the LKP.  364 
 365 
Figure 5 FT-IR spectra of (a) LKP NPs (b) unloaded NPs and (c) Pure LKP powder. 366 
Absorbance spectra are normalised and offset for clarity. 367 
3.5 IC50 determination of inhibitor 368 
The inhibitory activities of captopril (reference molecule) and LKP were determined using a 369 
synthetic substrate, HHL, and varying concentrations over the range 0.0001 – 10µM 370 
(captopril) and 0.001 - 10µM (LKP). The IC50 obtained was 0.006 ± 0.002 µM for captopril 371 
and 0.30 ± 0.08 µM for LKP. These values are consistent with previously reported values, 372 
which range from 0.001-0.039µM for Captopril and 0.2-0.32µM for LKP (Fujita & 373 
Yoshikawa 1999; Fujita et al. 2000; Henda et al. 2013). 374 
3.6 Accelerated stability analysis of LKP NPs 375 
In accelerated stability testing, a product is stressed at high temperatures and 376 
degradation/stability of the product at normal storage conditions is then predicted (Bajaj, 377 
Singla, & Sakhuja, 2012; Rauk, Guo, Hu, Cahya, & Weiss, 2014; Waterman & Adami, 378 
2005). A number of factors can affect the solution stability of NPs, for example, the pH of the 379 
aqueous solvents, light, oxygen, co-solutes, buffer salts, surfactants and antioxidants. 380 
Common degradation routes include hydrolysis/solvolysis, photolysis/oxidation and 381 
racemisation (Weber, Coester, Kreuter, & Langer, 2000). A number of groups have found 382 
that CL113 NPs synthesised by ionic gelation lose their integrity in aqueous media, even in 383 
the absence of enzymes (López-León, Carvalho, Seijo, Ortega-Vinuesa, & Bastos-González, 384 
2005). Jonassen et al. (2012) looked at the effect of different ionic strength over the course of 385 
a month; the main findings were that the most stable NPs with respect to the size and 386 
compactness of the particles were produced in saline conditions (Jonassen, Kjøniksen, & 387 
Hiorth, 2012). A similar study was also conducted, preparing NPs in different ionic strength 388 
and buffers, and results showed that the least stable NPs were produced in non-buffered 389 
solutions or low ionic solutions (López-León et al., 2005).  390 
The stability of formulations can be tested using a number of testing protocols, which include 391 
real time stability testing, accelerated stability testing, retained sample stability testing and 392 
cyclic temperature stress testing (Bajaj et al., 2012). In the current study, accelerated stability 393 
testing was used, by which NPs are subjected to stress and then assayed simultaneously to 394 
predict the likelihood of instability based upon the Arrhenius equation. Suspensions of NPs in 395 
buffered solutions (PBS pH 7), formulated at a ratio of 5.9 CL113:TPP (optimal LKP loaded 396 
NPs), were exposed to three different storage temperatures, 60°C, 70°C and 80°C, over a 397 
time course of 120, 300 and 720min at each temperature. Figure 6 shows the kinetic 398 
behaviour of the particle sizes at different temperatures. The stability of the NPs decreased 399 
with increasing temperature. At 60°C, no change in particle size was observed over the 400 
720min. Figure 6 indicates a more pronounced increase in both particle size and PDI at 70°C, 401 
while at 80°C, both particle size and PDI increase significantly over the time course. At this 402 
temperature, the particle size was seen to increase monotonically from 200 to 600nm, while 403 
the PDI increases from 0.4 to 0.7.  While some curvature is apparent in the trends at the 404 
highest temperature, within the present experimental error, an apparent zero order mechanism 405 
fitted better to all the data, compared to an apparent first or second order model.  406 
 407 
Figure 6 Particle size and PDI analysis of LKP loaded NPs exposed at (a) 60°C (b) 70°C and 408 
(c) 80°C over time periods of 120, 300 and 720min, respectively. N= 3 409 
An Arrhenius plot of the apparent zero order reaction rate constants, derived from the 410 
analysis of the individual experiments at the different temperatures, indicates that the kinetics 411 
of the particle size and PDI followed this temperature relationship, consistent with an energy 412 
activated process, with similar energies of activation for particle size and PDI (see Figure 7).  413 
The one-step nonlinear regression analysis of the kinetic experiments shows that the particle 414 
size fits to a zero order kinetic behaviour and an Arrhenius dependence with ln (kref@70C) = -415 
3±1 min
-1
 and an Ea of = 360±103 kJ/mol. For the PDI, a one-step nonlinear regression was 416 
fitted to zero order kinetics with an Arrhenius dependence of ln (kref@70°C) = -8.9± 0.3mins
-
417 
1
 and Ea =196± 33 kJ/mol. A linear correlation is evident between 1/T and ln k in figure 7. 418 
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From this analysis, it suggests the nanoparticle formulation would be stable (in terms of 419 
particle physico-chemical properties) in a neutral pH solution at ambient storage temperature, 420 
with negligible increases in particle size or PDI of the NPs, confirming the higher stability of 421 
NPs prepared in buffered solutions. Only after 90min destabilisation of NPs was observed at 422 
the highest temperature conditions. These results are in agreement with previous literature, 423 
reporting that when NPs are produced in salt or buffered environment, stability is improved 424 
(López-León et al., 2005).  425 
 426 
Figure 7 Arrhenius Plots for the (a) Particle Size and (b) PDI accelerated studies of LKP 427 
loaded NPs. N=3 428 
The results suggest either (i) swelling of the chitosan NPs in the aqueous environment (Bajpai 429 
& Maan, 2012) or (ii) agglomeration of chitosan NPs due to electrostatic interactions with an 430 
increase of temperature. In order to confirm the type of degradation, the zeta potential was 431 
assessed. Destabilisation of NP suspensions which would give rise to aggregation should be 432 
reflected in changes in ZP values when NPs aggregate. However, no significant changes were 433 
seen for the colloidal stability (i.e. ZP of LKP NPs). This suggests that swelling could be the 434 
primary mechanism of the CL113 nanoparticle changes with time, followed by destabilisation 435 
at higher temperatures and longer time (see figure 8). 436 
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 437 
Figure 8 Zeta potential analyses of LKP-loaded NPs at (a) 60°C, (b) 70°C and (c) 80°C. No 438 
significant changes were observed with One-Way ANOVA with Dunnetts’s post-test. Each 439 
value represents the mean ± SD (n=3) 440 
  In addition, DD of CL113 used for this experiment is greater than 85%, it has been 441 
previously reported that with an increase of DD the aggregation stability decreases due to the 442 
CL113 more prone to TPP bridging which causes it to become more lyophobic near 443 
physiological pH which may contribute to the stability of the NPs (Haung, Cai, & Lapitsky, 444 
2015). Overall, the accelerated experiments on LKP NPs indicate that the formulations will 445 
be stable under normal storage conditions. This could be due to the conditions (presence of 446 
salt) used to prepare the NPs, in addition to the strong bonding between the bioactive and 447 
complex. 448 
3.7 Cytotoxicity assessment of LKP nanoparticles 449 
The MTS assay was used to assess the cytotoxicity of LKP and LKP NPs. The therapeutic 450 
dose of LKP is 10mg/kg (Fujita et al., 2000; Fujita & Yoshikawa, 1999b). Hence, LKP 451 
loaded or unloaded NPs at the different concentrations (1, 5 and 10mM) when exposed to 452 
Caco2 (4h) and HepG2 (72h) cell lines. No cytotoxicity was observed for LKP, indicating 453 
negligible overall cytotoxicity of the formulation (figure 9). No significant changes were 454 
observed. A number of deviations were observed above 100% viability for NPs with and 455 
without LKP, proliferation may occur due to increase in fibroblasts production caused by the 456 
presence of polymeric chitosan (Rajam, Pulavendran, Rose, & Mandal, 2011) or interference 457 
of NPs with the cell assay (Casey et al., 2007).  458 
 459 
 460 
 461 
Figure 9 Cytotoxicity assessment of  LKP, unloaded NPs and  LKP NPs 462 
exposed for (a) 4h in Caco2 cell lines and (b) 72h in HepG2 cell line at 1mM, 5mM and 463 
10mM concentration. Percentage (%) of MTS converted was compared to untreated control. 464 
1-Way ANOVA with Dunnetts’s post-test *** P< 0.001, ** P< 0.01, N=3 465 
3.8 In vitro release studies 466 
The release of a bioactive can take place by several different mechanisms, for example 467 
surface erosion, disintegration, diffusion and desorption (Hosseini, Zandi, Rezaei, & 468 
Farahmandghavi, 2013). Such a phenomenon can be influenced by a number of factors such 469 
as the type of polymer used, the polymeric swelling capability, the solute diffusion and 470 
material degradation (Fu & Kao, 2009; Siepmann & Göpferich, 2001). The in vitro LKP 471 
release profiles of the NP formulation in SGF and SIF were measured over 24h, using RP-472 
HPLC at 220nm at different time points. The site of target for LKP is in the jejunum, small 473 
intestine, therefore it is important to bypass the acidic stomach environment. LKP NPs results 474 
showed an initial burst followed by a slow release. Similar results were reported by other 475 
groups, Hosseini et al. 2013 and Luo et al. 2010. Hosseini et al. 2013, they observed a 476 
“biphasic release” mechanism (initial burst followed by slower release) with oregano 477 
essential oil when encapsulated into CL113 NPs. Luo et al. 2010, encapsulated selenite in 478 
chitosan NPs, demonstrating the effect of CL113 concentration on the release profile. They 479 
found that, at high concentrations of chitosan, more dense particles were found which 480 
ultimately lowered the epithelial membrane permeability. Conflicting results have been 481 
reported of the release mechanism of chitosan nanoparticles. Some groups observed the 482 
inability of chitosan based nanoparticles to sustain the release of an active following an initial 483 
burst release at higher ratios of CL113 and TPP (Stoica & Ion, 2013). Others reported a 484 
controlled release; for example, Nallamuthu, Devi, & Khanum, (2015) observed the 69% 485 
release of chlorogenic acid over 100 h. Release profiles at 1.5mg/ml CL113 also showed a 486 
burst within the first 30min in the SGF followed by a slower release from 30min to 2h then a 487 
more slow sustained release up to 24h, as shown in figure 10. For LKP NPs, the initial burst 488 
may possibly represent loosely bound LKP around the CL113 NP. Within the first hour, 62% 489 
±3 and 74% ±4 LKP was released in (a) SGF and (b) SIF, significance was observed for SGF 490 
vs SIF using a t-test, where P = 0.0074, respectively (figure 10). 12% more release was 491 
observed in the SIF (site of target) at pH 6.8. Chitosan has an isoelectric point of 6.5, at 492 
which pH chitosan holds a charge of zero (no charge), causing it to become unstable and 493 
precipitate out; consequently releasing more of the loaded peptide. It has been suggested by 494 
Gan & Wang, (2007) that a burst release of protein molecules may correspond to the fast 495 
swelling and degradation of the nanoparticles. This swelling phenomenon can be observed in 496 
(figure 10) After 1h, a slower release is observed, this may be attributed to the more strongly 497 
bound LKP loaded within the CL113 nanoparticle. A burst release has previously been 498 
reported from other groups working with chitosan NPs, Sarmento et al. (2007) showed a 499 
similar undesirable burst of 50% insulin chitosan NPs when complexed with alginate. Ryan et 500 
al. (2013) also reported an initial burst of 40% of salmon calcitonin when complexed into a 501 
NPs system using chitosan and hyaluronic acid. For oral delivery systems, NPs remain in the 502 
system for up to 6h after intake. Our studies show after 6h up to 85% release was obtained. 503 
However, a prolonged release is desired. Additional of an outer surface coating is a technique 504 
which has been widely used by a number of researchers in order to improve the integrity of 505 
the NPs and to better control the release profile (Elgadir et al., 2015). A popular approach to 506 
yield coated chitosan NPs is by polyelectrolyte complexation, which exploits the interaction 507 
between positively charged chitosan and negatively charged polyelectrolytes such as alginate 508 
(Garrait, Beyssac and Subirade, 2014), dextran (Sarmento et al., 2006), hyaluronic acid 509 
(Mero et al., 2014) or zein (Luo, Teng and Wang, 2012). Further work on LKP encapsulation 510 
will involve the polyelectrolyte complexation of LKP to achieve the desired release. 511 
. 512 
  513 
Figure 10 Cumulative release profile of LKP from NPs in (a) SGF and (b) SIF for 24h.  514 
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4. Conclusions 515 
LKP loaded NPs were formulated successfully by applying the ionotropic gelation technique. 516 
The optimal NPs were found at a ratio 5.9:1 (CL113: TPP), using the design of experiment 517 
approach, which resulted in reproducibility of the desirable physico-chemical characteristics. 518 
Optimally LKP NPs were spheroidal particles of size ~200nm, as shown by SEM, and had 519 
enhanced colloidal stability compared to the unloaded particles. A 5.9:1 ratio provided high 520 
encapsulation efficiency of 65±3% with loading capacity of approximately 5±0.8 %. Stability 521 
analysis showed long term physico-chemical stability. ACE inhibitory studies presented no 522 
change in bioactivity of LKP over the different temperature conditions and after formulation 523 
indicating it is quite stable. In addition, no cytotoxicity was observed from both the LKP 524 
loaded and unloaded NPs. In vitro release studies indicated an initial burst within 1h, 525 
suggesting the presence of more loosely bound tripeptide in the nanoparticle complex, 526 
followed by peptide bounded within the nanoparticle which is released at a slower rate. 527 
Chitosan based delivery systems is a feasible for the formulation of bioactive peptide, 528 
physicochemical analysis and stability was efficient. The present results indicate that the 529 
addition of an enteric coating to is recommended in order to bypass the stomach acidic pH 530 
conditions, providing am efficient delivery system. 531 
Acknowledgements  532 
This project is funded by an Irish Department of Agriculture Food Institutional Research 533 
Measure (FIRM) grant ‘NUTRADEL’ grant number 11F042. Special thanks to Dr Anne 534 
Shanahan for the assistance in image analysis.  535 
References 536 
Abdel-Hafez, S. M., Hathout, R. M., & Sammour, O. a. (2014a). Towards better modeling of 537 
chitosan nanoparticles production: Screening different factors and comparing two 538 
experimental designs. International Journal of Biological Macromolecules, 64, 334–539 
340. http://doi.org/10.1016/j.ijbiomac.2013.11.041 540 
Abdel-Hafez, S. M., Hathout, R. M., & Sammour, O. a. (2014b). Towards better modeling of 541 
chitosan nanoparticles production: Screening different factors and comparing two 542 
experimental designs. International Journal of Biological Macromolecules, 64, 334–543 
340. http://doi.org/10.1016/j.ijbiomac.2013.11.041 544 
Acton, Q. A. (2012). Advances in Nanotechnology Research and Application: 2012 Edition. 545 
ScholarlyEditions. Retrieved from https://books.google.ie/books?id=jYeUaTkR9P8C 546 
Bajaj, S., Singla, D., & Sakhuja, N. (2012). Stability testing of pharmaceutical products. 547 
Journal of Applied Pharmaceutical Science, 2(3), 129–138. 548 
http://doi.org/10.7324/JAPS.2012.2322 549 
Bajpai, J., & Maan, G. K. (2012). Preparation , Characterization and Water Uptake Behavior 550 
of Polysaccharide Based Nanoparticles Swelling behavior of nanoparticles. Progresses 551 
in Nanotechnology and Nanomaterials, 1(1), 9–17. 552 
Berilyn, P., So, T., Rubio, P., Lirio, S., Macabeo, A. P., Huang, H.-Y., … Villaflores, O. B. 553 
(2016). In&nbsp;vitro angiotensin I converting enzyme inhibition by a peptide isolated 554 
from Chiropsalmus quadrigatus Haeckel (box jellyfish) venom hydrolysate. Toxicon : 555 
Official Journal of the International Society on Toxinology, 119, 77–83. 556 
http://doi.org/10.1016/j.toxicon.2016.04.050 557 
Bezerra, M. A., Santelli, R. E., Oliveira, E. P., Villar, L. S., & Escaleira, L. a. (2008). 558 
Response surface methodology (RSM) as a tool for optimization in analytical chemistry. 559 
Talanta, 76(5), 965–977. http://doi.org/10.1016/j.talanta.2008.05.019 560 
Bougatef, A., Nedjar-Arroume, N., Ravallec-Plé, R., Leroy, Y., Guillochon, D., Barkia, A., & 561 
Nasri, M. (2008). Angiotensin I-converting enzyme (ACE) inhibitory activities of 562 
sardinelle (Sardinella aurita) by-products protein hydrolysates obtained by treatment 563 
with microbial and visceral fish serine proteases. Food Chemistry, 111(2), 350–356. 564 
http://doi.org/10.1016/j.foodchem.2008.03.074 565 
Braithwaite, M. C., Tyagi, C., Tomar, L. K., Kumar, P., Choonara, Y. E., & Pillay, V. (2014). 566 
Nutraceutical-based therapeutics and formulation strategies augmenting their efficiency 567 
to complement modern medicine: An overview. Journal of Functional Foods. 568 
http://doi.org/10.1016/j.jff.2013.09.022 569 
Brauner, N., & Shacham, M. (1997). Statistical analysis of linear and nonlinear correlation of 570 
the Arrhenius equation constants. Chemical Engineering and Processing: Process 571 
Intensification, 36(3), 243–249. http://doi.org/10.1016/S0255-2701(96)04186-4 572 
Brayden, D. J., Gleeson, J., & Walsh, E. G. (2014). A head-to-head multi-parametric high 573 
content analysis of a series of medium chain fatty acid intestinal permeation enhancers 574 
in Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics, 88(3), 830–575 
839. http://doi.org/10.1016/j.ejpb.2014.10.008 576 
British Pharmacopoeia Commission. (2016). British Pharmacopoeia: Appendix XII B. 577 
Dissolution. London: TSO. 578 
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013). Basics and recent advances in peptide and 579 
protein drug delivery. Therapeutic Delivery, 4(11), 1443–67. 580 
http://doi.org/10.4155/tde.13.104 581 
Calderon L., Harris, R., Cordoba-Diaz, M., Elorza, M., Elorza, B., Lenoir, J., … Cordoba-582 
Diaz, D. (2013). Nano and microparticulate chitosan-based systems for antiviral topical 583 
delivery. European Journal of Pharmaceutical Sciences, 48, 216–222. 584 
http://doi.org/10.1016/j.ejps.2012.11.002 585 
Calvo, P., Remu, C., Pez, N.-L., Vila-Jato, J. L., & Alonso, M. J. (1997). Novel Hydrophilic 586 
Chitosan–Polyethylene Oxide Nanoparticles as Protein Carriers. Jounal of Applied 587 
Polymer Science, 63(1), 125–132. http://doi.org/10.1002/(SICI)1097-588 
4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 589 
Calvo, P., Remunan‐Lopez, C., Vila‐Jato, J. L., & Alonso, M. J. (1997). Novel hydrophilic 590 
chitosan‐polyethylene oxide nanoparticles as protein carriers. Journal of Applied 591 
Polymer Science, 63(1), 125–132. 592 
Casey, A., Herzog, E., Davoren, M., Lyng, F. M., Byrne, H. J., & Chambers, G. (2007). 593 
Spectroscopic analysis confirms the interactions between single walled carbon 594 
nanotubes and various dyes commonly used to assess cytotoxicity. Carbon, 45(7), 1425–595 
1432. http://doi.org/10.1016/j.carbon.2007.03.033 596 
Choonara, B. F., Choonara, Y. E., Kumar, P., Bijukumar, D., du Toit, L. C., & Pillay, V. 597 
(2014). A review of advanced oral drug delivery technologies facilitating the protection 598 
and absorption of protein and peptide molecules. Biotechnology Advances, 32(7), 1269–599 
1282. http://doi.org/10.1016/j.biotechadv.2014.07.006 600 
Chuah, A. M., Kuroiwa, T., Ichikawa, S., Kobayashi, I., & Nakajima, M. (2009). Formation 601 
of biocompatible nanoparticles via the self-assembly of chitosan and modified lecithin. 602 
Journal of Food Science, 74(1). http://doi.org/10.1111/j.1750-3841.2008.00985.x 603 
de Moura, M. R., Aouada, F. A., Avena-Bustillos, R. J., McHugh, T. H., Krochta, J. M., & 604 
Mattoso, L. H. C. (2009). Improved barrier and mechanical properties of novel 605 
hydroxypropyl methylcellulose edible films with chitosan/tripolyphosphate 606 
nanoparticles. Journal of Food Engineering, 92(4), 448–453. 607 
http://doi.org/10.1016/j.jfoodeng.2008.12.015 608 
de Pinho Neves, A. L., Milioli, C. C., Müller, L., Riella, H. G., Kuhnen, N. C., & Stulzer, H. 609 
K. (2014). Factorial design as tool in chitosan nanoparticles development by ionic 610 
gelation technique. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 611 
445(2014), 34–39. http://doi.org/10.1016/j.colsurfa.2013.12.058 612 
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y. J., & Préat, V. (2006). Nanoparticles as 613 
potential oral delivery systems of proteins and vaccines: A mechanistic approach. 614 
Journal of Controlled Release. http://doi.org/10.1016/j.jconrel.2006.08.013 615 
Franca, E. F., Freitas, L. C. G., & Lins, R. D. (2011). Chitosan molecular structure as a 616 
function of N-acetylation. Biopolymers, 95(7), 448–460. 617 
http://doi.org/10.1002/bip.21602 618 
Fu, Y., & Kao, W. J. (2009). Drug release kinetics and transport mechanisms from semi-619 
interpenetrating networks of gelatin and poly(ethylene glycol) diacrylate. 620 
Pharmaceutical Research, 26(9), 2115–2124. http://doi.org/10.1007/s11095-009-9923-1 621 
Fujita, H., & Yoshikawa, M. (1999a). LKPNM: A prodrug-type ACE-inhibitory peptide 622 
derived from fish protein. Immunopharmacology, 44(1–2), 123–127. 623 
http://doi.org/10.1016/S0162-3109(99)00118-6 624 
Fujita, Yokoyama, Yoshikawa, M., Iroyukifujita, H., & Eiichiyokoyama, K. (2000). 625 
Classification and Antihypertensive Activity of Angiotensin I-Converting Enzyme 626 
Inhibitory Peptides Derived from Food Proteins. Journal of Food Science, 65(4), 564–627 
569. http://doi.org/10.1111/j.1365-2621.2000.tb16049.x 628 
Fujita, & Yoshikawa, M. (1999b). LKPNM: A prodrug-type ACE-inhibitory peptide derived 629 
from fish protein. Immunopharmacology, 44(1–2), 123–127. 630 
http://doi.org/10.1016/S0162-3109(99)00118-6 631 
García, M., Forbe, T., & Gonzalez, E. (2010). Potential applications of nanotechnology in the 632 
agro-food sector. Ciência E Tecnologia de Alimentos, 30(3), 573–581. 633 
http://doi.org/10.1590/S0101-20612010000300002 634 
Gleeson, J. P., Heade, J., Ryan, S. M. M., & Brayden, D. J. (2015). Stability, toxicity and 635 
intestinal permeation enhancement of two food-derived antihypertensive tripeptides, Ile-636 
Pro-Pro and Leu-Lys-Pro. TL  - 71. Peptides, 71 VN-r, 1–7. 637 
http://doi.org/10.1016/j.peptides.2015.05.009 638 
Haung, Y., Cai, Y., & Lapitsky, Y. (2015). Factors Affecting the Stability of 639 
Chitosan/Tripolyphosphate Micro- and Nanogels: Resolving the Opposing Findings. J. 640 
Mater. Chem. B, 3, 5957–5970. http://doi.org/10.1039/C5TB00431D 641 
Henda, Y. Ben, Labidi, A., Arnaudin, I., Bridiau, N., Delatouche, R., Maugard, T., … 642 
Bordenave-Juchereau, S. (2013). Measuring angiotensin-I converting enzyme inhibitory 643 
activity by micro plate assays: Comparison using marine cryptides and tentative 644 
threshold determinations with captopril and losartan. Journal of Agricultural and Food 645 
Chemistry, 61, 10685–10690. http://doi.org/10.1021/jf403004e 646 
Henriksson, G., Englund, A.-K., Johansson, G., & Lundahl, P. (1995). Calculation of the 647 
isoelectric points of native proteins with spreading of pKa values. Electrophoresis, 648 
16(1), 1377–1380. http://doi.org/10.1002/elps.11501601227 649 
Hosseini, S. F., Zandi, M., Rezaei, M., & Farahmandghavi, F. (2013). Two-step method for 650 
encapsulation of oregano essential oil in chitosan nanoparticles: Preparation, 651 
characterization and in vitro release study. Carbohydrate Polymers, 95(1), 50–56. 652 
http://doi.org/10.1016/j.carbpol.2013.02.031 653 
Hosseinzadeh, H., Atyabi, F., Dinarvand, R., & Ostad, S. N. (2012). Chitosan-Pluronic 654 
nanoparticles as oral delivery of anticancer gemcitabine: Preparation and in vitro study. 655 
International Journal of Nanomedicine, 7, 1851–1863. 656 
http://doi.org/10.2147/IJN.S26365 657 
Jarudilokkul, S., Tongthammachat, A., & Boonamnuayvittaya, V. (2011). Preparation of 658 
chitosan nanoparticles for encapsulation and release of protein. Korean Journal of 659 
Chemical Engineering, 28(5), 1247–1251. http://doi.org/10.1007/s11814-010-0485-z 660 
Jonassen, H., Kjøniksen, A. L., & Hiorth, M. (2012). Stability of chitosan nanoparticles 661 
cross-linked with tripolyphosphate. Biomacromolecules, 13(11), 3747–3756. 662 
http://doi.org/10.1021/bm301207a 663 
Lahogue, V., Réhel, K., Taupin, L., Haras, D., & Allaume, P. (2010). A HPLC-UV method 664 
for the determination of angiotensin I-converting enzyme (ACE) inhibitory activity. 665 
Food Chemistry, 118(3), 870–875. http://doi.org/10.1016/j.foodchem.2009.05.080 666 
Lakshmi, P., & Kumar, G. A. (2010). Nanosuspension technology: A review. International 667 
Journal of Pharmacy and Pharmaceutical Sciences. 668 
http://doi.org/10.2174/0929866521666140807114240 669 
Li, Y., Sadiq, F., Fu, L., Zhu, H., Zhong, M., & Sohail, M. (2016). Identification of 670 
Angiotensin I-Converting Enzyme Inhibitory Peptides Derived from Enzymatic 671 
Hydrolysates of Razor Clam Sinonovacula constricta. Marine Drugs, 14(6), 110. 672 
http://doi.org/10.3390/md14060110 673 
López-León, T., Carvalho, E. L. S., Seijo, B., Ortega-Vinuesa, J. L., & Bastos-González, D. 674 
(2005). Physicochemical characterization of chitosan nanoparticles: electrokinetic and 675 
stability behavior. Journal of Colloid and Interface Science, 283(2), 344–351. 676 
http://doi.org/10.1016/j.jcis.2004.08.186 677 
Luo, Y., Zhang, B., Cheng, W. H., & Wang, Q. (2010). Preparation, characterization and 678 
evaluation of selenite-loaded chitosan/TPP nanoparticles with or without zein coating. 679 
Carbohydrate Polymers, 82(3), 942–951. http://doi.org/10.1016/j.carbpol.2010.06.029 680 
Ma, G. (2014). Microencapsulation of protein drugs for drug delivery: Strategy, preparation, 681 
and applications. Journal of Controlled Release, 193, 324–340. 682 
http://doi.org/10.1016/j.jconrel.2014.09.003 683 
Madureira, A. R., Pereira, A., & Pintado, M. (2016). Chitosan nanoparticles loaded with 2,5-684 
dihydroxybenzoic acid and protocatechuic acid: Properties and digestion. Journal of 685 
Food Engineering, 174, 8–14. http://doi.org/10.1016/j.jfoodeng.2015.11.007 686 
Mohammadpour Dounighi, N., Eskandari, R., Avadi, M. R., Zolfagharian, H., Mir 687 
Mohammad Sadeghi, A., & Rezayat, M. (2012). Preparation and in vitro 688 
characterization of chitosan nanoparticles containing Mesobuthus eupeus scorpion 689 
venom as an antigen delivery system. Journal of Venomous Animals and Toxins 690 
Including Tropical Diseases, 18(1), 44–52. Retrieved from 691 
http://www.scopus.com/inward/record.url?eid=2-s2.0-692 
84859077437&partnerID=40&md5=781a81bf61973593aac773cb8b03e495 693 
Nallamuthu, I., Devi, A., & Khanum, F. (2015). Chlorogenic acid loaded chitosan 694 
nanoparticles with sustained release property, retained antioxidant activity and enhanced 695 
bioavailability. Asian Journal of Pharmaceutical Sciences, 10(3), 203–211. 696 
http://doi.org/10.1016/j.ajps.2014.09.005 697 
Neves, A. R., Martins, S., Segundo, M. A., & Reis, S. (2016). Nanoscale delivery of 698 
resveratrol towards enhancement of supplements and nutraceuticals. Nutrients, 8(3), 1–699 
14. http://doi.org/10.3390/nu8030131 700 
Patel, A., Patel, M., Yang, X., & Mitra, A. K. (2014). Recent advances in protein and peptide 701 
drug delivery: a special emphasis on polymeric nanoparticles. Protein and Peptide 702 
Letters, 21(11), 1102. 703 
Quiñones, M., Margalef, M., Arola-Arnal, A., Muguerza, B., Miguel, M., & Aleixandre, A. 704 
(2015). The blood pressure effect and related plasma levels of flavan-3-ols in 705 
spontaneously hypertensive rats. Food & Function, 6(11), 3479–89. 706 
http://doi.org/10.1039/c5fo00547g 707 
R Core Team. (2015). R: A language and environment for statistical computing. R 708 
Foundation for Statistical Computing. Austria,Vienna: R Foundation for Statistical 709 
Computing,. Retrieved from http://www.r-project.org/ 710 
Rajam, M., Pulavendran, S., Rose, C., & Mandal, A. B. (2011). Chitosan nanoparticles as a 711 
dual growth factor delivery system for tissue engineering applications. International 712 
Journal of Pharmaceutics, 410(1–2), 145–152. 713 
http://doi.org/10.1016/j.ijpharm.2011.02.065 714 
Rauk, A. P., Guo, K., Hu, Y., Cahya, S., & Weiss, W. F. (2014). Arrhenius time-scaled least 715 
squares: a simple, robust approach to accelerated stability data analysis for bioproducts. 716 
Journal of Pharmaceutical Sciences, 103(8), 2278–86. http://doi.org/10.1002/jps.24063 717 
Rinaudo, M. (2006). Chitin and chitosan: Properties and applications. Progress in Polymer 718 
Science, 31(7), 603–632. http://doi.org/10.1016/j.progpolymsci.2006.06.001 719 
Ryan, S. M., McMorrow, J., Umerska, A., Patel, H. B., Kornerup, K. N., Tajber, L., … 720 
Brayden, D. J. (2013). An intra-articular salmon calcitonin-based nanocomplex reduces 721 
experimental inflammatory arthritis. Journal of Controlled Release, 167(2), 120–129. 722 
http://doi.org/10.1016/j.jconrel.2013.01.027 723 
Segura-Campos, M., Chel-Guerrero, L., Betancur-Ancona, D., & Hernandez-Escalante, V. 724 
M. (2011). Bioavailability of Bioactive Peptides. Food Reviews International, 27(3), 725 
213–226. http://doi.org/10.1080/87559129.2011.563395 726 
Sharpe, L. A., Daily, A. M., Horava, S. D., & Peppas, N. A. (2014). Therapeutic applications 727 
of hydrogels in oral drug delivery. Expert Opinion on Drug Delivery, 11(6), 901–15. 728 
http://doi.org/10.1517/17425247.2014.902047 729 
Siepmann, J., & Göpferich, A. (2001). Mathematical modeling of bioerodible, polymeric 730 
drug delivery systems. Advanced Drug Delivery Reviews, 48(2–3), 229–247. 731 
http://doi.org/10.1016/S0169-409X(01)00116-8 732 
Silva, N. C., Silva, S., Sarmento, B., & Pintado, M. (2013). Chitosan nanoparticles for 733 
daptomycin delivery in ocular treatment of bacterial endophthalmitis. Drug Delivery, 734 
7544, 1–9. http://doi.org/10.3109/10717544.2013.858195 735 
Singh, M. R., Singh, D., Saraf, S., & Saraf, S. (2011). Formulation optimization of controlled 736 
delivery system for antihypertensive peptide using response surface methodology. Am J 737 
Drug Discov Dev, 1(3), 174–187. http://doi.org/10.3923/ajdd.2011.174.187 738 
Sureshkumar, M. K., Das, D., Mallia, M. B., & Gupta, P. C. (2010). Adsorption of uranium 739 
from aqueous solution using chitosan-tripolyphosphate (CTPP) beads. Journal of 740 
Hazardous Materials, 184(1–3), 65–72. http://doi.org/10.1016/j.jhazmat.2010.07.119 741 
Takahashi, M., Uechi, S., Takara, K., Asikin, Y., & Wada, K. (2009). Evaluation of an Oral 742 
Carrier System in Rats: Bioavailability and Antioxidant Properties of Liposome-743 
Encapsulated Curcumin. Journal of Agricultural and Food Chemistry, 57(19), 9141–744 
9146. http://doi.org/10.1021/jf9013923 745 
Vimal, S., Abdul Majeed, S., Taju, G., Nambi, K. S. N., Sundar Raj, N., Madan, N., … Sahul 746 
Hameed, A. S. (2013). Chitosan tripolyphosphate (CS/TPP) nanoparticles: preparation, 747 
characterization and application for gene delivery in shrimp. Acta Tropica, 128(3), 486–748 
93. http://doi.org/10.1016/j.actatropica.2013.07.013 749 
Waterman, K. C., & Adami, R. C. (2005). Accelerated aging: Prediction of chemical stability 750 
of pharmaceuticals. International Journal of Pharmaceutics, 293(1–2), 101–125. 751 
http://doi.org/10.1016/j.ijpharm.2004.12.013 752 
Weber, C., Coester, C., Kreuter, J., & Langer, K. (2000). Desolvation process and surface 753 
characterisation of protein nanoparticles. International Journal of Pharmaceutics, 754 
194(1), 91–102. http://doi.org/10.1016/S0378-5173(99)00370-1 755 
Woranuch, S., & Yoksan, R. (2013). Eugenol-loaded chitosan nanoparticles: I. Thermal 756 
stability improvement of eugenol through encapsulation. Carbohydrate Polymers, 96(2), 757 
578–85. http://doi.org/10.1016/j.carbpol.2012.08.117 758 
Yamaguchi, N., Kawaguchi, K., & Yamamoto, N. (2009). Study of the mechanism of 759 
antihypertensive peptides VPP and IPP in spontaneously  hypertensive rats by DNA 760 
microarray analysis. European Journal of Pharmacology, 620(1–3), 71–77. 761 
http://doi.org/10.1016/j.ejphar.2009.08.005 762 
Yao, M., McClements, D. J., & Xiao, H. (2015). Improving oral bioavailability of 763 
nutraceuticals by engineered nanoparticle-based delivery systems. Current Opinion in 764 
Food Science, 2, 14–19. http://doi.org/10.1016/j.cofs.2014.12.005 765 
Yoon, H. Y., Son, S., Lee, S. J., You, D. G., Yhee, J. Y., Park, J. H., … Pomper, M. G. 766 
(2014). Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: 767 
Sequential delivery of doxorubicin and Bcl-2 siRNA. Scientific Reports, 4, 6878. 768 
http://doi.org/10.1038/srep06878 769 
Zhou, M., Du, K., Ji, P., & Feng, W. (2012). Molecular mechanism of the interactions 770 
between inhibitory tripeptides and angiotensin-converting enzyme. Biophysical 771 
Chemistry, 168–169, 60–66. http://doi.org/10.1016/j.bpc.2012.05.002 772 
 773 
Supplementary Material  
S1: Fitted results of 3rd order polynomial regression against the PDI, ZP, AE % and particle 
size for LKP-loaded NPs 
Polynomial regression equation: 
a +bRatio + cRatio
2
 +dRatio
3
 
Coefficient of 
determination (R
2
) 
Size (nm)  
a= - 284.90         
b=  293.40 
c= - 64.68            
d=  4.51 
R
2
 = 85.6% 
 
PDI  
a = 2.31              
b= - 0.88 
c = 0.12              
d = 0.01 
R
2
 = 83.2% 
 
ZP (mV)  
a = - 16.80         
b = 31.05 
c = - 6.36           
d = 0.42 
R
2
 = 76.1% 
 
AE (%)  
a = 335.60              
b = - 202.40 
c = 43.79                
d = - 2.90 
R
2
 = 50.2% 
 
 
S2: Loading capacities of LKP-loaded NPs, n=3 
Sample  CL113 (mg/ml) TPP (mg/ml) Ratio (CL113/TPP) LC % 
1 1.64 0.21 8.0 2.2±0.01 
2 1.52 0.33 4.5 3.3±0.00 
3 1.58 0.27 5.9 2.3±0.08 
4 1.45 0.40 3.6 2.7±0.03 
5 1.39 0.46 3.0 2.8±0.02 
 
